Browsing Tag
Cosentyx
5 posts
Novartis profit plunges 70% after $1.9bn drug impairment despite stronger core earnings
Novartis reported $14.52 billion in quarterly sales and an 11% increase in core operating profit, but statutory net income declined 70% following a major impairment related to its investigational medicine del-desiran. Strong oncology and immunology sales are helping offset generic competition, while the drug pipeline presents new financial uncertainties.
How pediatric biologic approvals are transforming hidradenitis suppurativa treatment
Novartis AG expands Cosentyx approval to adolescents with hidradenitis suppurativa. Discover what this means for dermatology biologics and investors.
Novartis achieves 22% rise in core operating income, driven by innovative medicines
Novartis has reported a stellar performance for the fourth quarter of 2024, showcasing impressive growth across its core…
FDA approves Novartis’ Cosentyx for hidradenitis suppurativa treatment
Novartis, a global leader in immuno-dermatology and rheumatology, announced the U.S. Food and Drug Administration’s approval of Cosentyx…
EC approves dosing flexibility for Novartis’s Cosentyx in psoriatic arthritis treatment
The European Commission (EC) has granted Novartis approval for a significant update to the label of its psoriatic…